People · Operator
Named in public records as an officer, director or promoter · active 2008–2025 · Pharmaceuticals, Biotechnology, Other Health Care, Other Energy
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Avilar Therapeutics, Inc. | — | Pharmaceuticals | Series C | $75.3M | $2.3B | 2020 |
| Link Medicine Corp | — | Biotechnology | Series B | $64.8M | $190.8M | 2008 |
| Afferent Pharmaceuticals, Inc. | — | Other Health Care | Series C | $58.1M | $1.3B | 2009 |
| Sustainx Inc | — | Other Energy | Series B | $38.4M | $232.1M | 2009 |
| Obsidian Therapeutics, Inc. | — | Biotechnology | Series B | $32.4M | $1.3B | 2017 |
| SightStream Biotherapeutics, Inc. | — | Biotechnology | Seed | $5.1M | $4.3M | 2022 |
| Nayan Therapeutics, Inc. | — | Biotechnology | Seed | $3.0M | $133.2M | 2019 |
David Neafus at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Neafus on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Joshua Resnick | 2 | 12 |
| Milind Deshpande | 2 | 4 |
| Michael Ross | 1 | 18 |
| Peter Barrett | 1 | 18 |
| Terry McGuire | 1 | 8 |
| David Guyer | 1 | 8 |
| David Prend | 1 | 7 |
| Mitchell S. Bloom | 1 | 7 |
| Michael Gilman | 1 | 6 |
| Paulina Hill | 1 | 5 |
| JASON GARDNER | 1 | 5 |
| Kevin Starr | 1 | 5 |
| Paul McDermott | 1 | 5 |
| Karen Hong | 1 | 4 |
| Kathleen Sereda Glaub | 1 | 3 |
| Reza Dana | 1 | 3 |
| Martin Freed | 1 | 3 |
| Robert Millman | 1 | 3 |
| Jason Werner | 1 | 3 |
| Daniel Grau | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.